Trials / Completed
CompletedNCT00606697
A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia
Vestipitant and Vofopitant 2 Day PSG Study for Insomnia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
Patients with Primary Insomnia will be treated with GW597599 and GR205171 to evaluate the efficacy in the sleep difficulties associated with insomnia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GR205171 | 10 milligrams (mg) |
| DRUG | GW597599 | 15 mg |
Timeline
- Start date
- 2007-12-19
- Primary completion
- 2008-05-07
- Completion
- 2008-05-07
- First posted
- 2008-02-04
- Last updated
- 2017-07-11
Locations
10 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00606697. Inclusion in this directory is not an endorsement.